Arch Biopartners Receives Permission From U.S. FDA to Proceed With Phase II Acute…
Approval from FDA to initiate Phase II trial with LSALT peptide to target cardiac surgery-associated acute kidney injury (CS-AKI)LSALT peptide targets dipeptidase-1 (DPEP-1), an enzyme…